| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Article |
From the Department of Internal Medicine, Hypertension Division, University of Texas Southwestern Medical Center, Dallas, Tex.
Correspondence to Gail D. Thomas, PhD, University of Texas Southwestern Medical Center, Hypertension Division, 5323 Harry Hines Blvd, Dallas, TX 75390-8586. E-mail gail.thomas{at}utsouthwestern.edu
Abstract
AbstractSkeletal muscle perfusion during exercise is impaired in heart failure, but the underlying mechanisms are poorly understood. One possibility is that sympathetic vasoconstriction is enhanced in exercising muscle in heart failure as a result of impaired counterregulatory mechanisms that normally act to attenuate vasoconstrictor responses. In healthy animals, sympathetic vasoconstriction in contracting skeletal muscle is attenuated by endogenously produced nitric oxide (NO). Because the NO pathway may be dysfunctional in heart failure, we hypothesized that reduced NO in contracting muscle would result in enhanced sympathetic vasoconstriction. In sham rats and rats with chronic myocardial infarctions (MIs) produced by coronary artery ligation, we measured arterial pressure and femoral artery blood flow responses to sympathetic nerve stimulation (1, 2.5, and 5 Hz) in resting and contracting hindlimb. In resting hindlimb, sympathetic stimulation decreased femoral vascular conductance similarly in sham and MI rats. In contracting hindlimb, these vasoconstrictor responses were attenuated to a greater extent in sham than in MI rats. NO synthase inhibition enhanced sympathetic vasoconstriction in contracting hindlimb of sham, but not MI, rats. Conversely, infusion of L-arginine or a superoxide scavenger, tempol or tiron, attenuated sympathetic vasoconstriction in contracting hindlimb of MI rats. NO synthase expression was similar, but malondialdehyde (a marker of free radical damage) was greater in skeletal muscle from MI than from sham rats. These data suggest that impaired metabolic modulation of sympathetic vasoconstriction in contracting skeletal muscle of MI rats is a consequence of superoxide-mediated disruption of the NO pathway.
Key Words: vasoconstriction oxidant stress nitric oxide skeletal muscle heart failure
Activation of the sympathetic nervous system plays an essential role in the cardiovascular response to exercise. Sympathetic activation causes vasoconstriction in regions such as the renal and splanchnic circulations, which redistributes cardiac output to the exercising muscles. Sympathetic activation also occurs in exercising muscle,1 but the vasoconstrictor response appears to be blunted in part by local metabolic products of contraction.2 3 4 Such metabolic modulation is particularly evident in the small resistance arterioles of the muscle microcirculation,2 which may serve to optimally distribute blood flow within the active muscle.
Nitric oxide (NO) is thought to be one of the key substances
produced in contracting skeletal muscle that effectively opposes
sympathetic
vasoconstriction.3 4 5
Although both the endothelial and neuronal isoforms of
NO synthase (eNOS and nNOS, respectively) are expressed in skeletal
muscle,6 7 nNOS
appears to be an important source of NO production during
contraction as demonstrated by the impaired modulation of
-adrenergic vasoconstriction in the contracting hindlimb of nNOS
knockout mice.4 This
impairment also is evident in boys with Duchenne muscular dystrophy
(DMD)5 and in mdx
mice,4 a model of DMD in
which a primary deficiency of the cytoskeletal protein dystrophin
results in a secondary reduction of skeletal muscle
nNOS.8 Recurrent
ischemia caused by unopposed sympathetic vasoconstriction in
the nNOS-deficient muscles of DMD patients may contribute to exercise
intolerance in this rare disease. Whether a similar mechanism might
contribute to the exercise intolerance observed in a much more common
condition such as heart failure is unknown.
Increasing evidence suggests that NO-mediated vasodilation is impaired in heart failure.9 10 11 During exercise, NO production is reduced in heart failure patients compared with healthy controls.12 Additionally, NOS inhibition reduces blood flow to exercising muscles in healthy rats and humans, but not in those with heart failure.13 14 The reasons for the apparent NO deficiency in these studies were not investigated. One possibility is that NOS expression is reduced10 15 ; however, this has not been a consistent finding.15 16 Another possibility is that NO bioavailability, rather than production, is limited in heart failure. Reactive oxygen species, in particular superoxide anion (O2-), are known to rapidly inactivate NO. Recent studies in animals and humans have shown that oxidative stress is increased in heart failure, as evidenced directly by increased myocardial and aortic production of reactive oxygen species16 17 and indirectly by circulating markers of free radicalinduced cellular damage.18 19 20 Whether heart failure also increases oxidative stress in skeletal muscle and how this might impact muscle blood flow regulation are currently unknown.
On the basis of these observations, we hypothesized that metabolic modulation of sympathetic vasoconstriction in skeletal muscle is impaired in chronic heart failure. We further hypothesized that this impairment is mediated in part by NO deficiency caused by decreased skeletal muscle NOS expression and/or O2--mediated disruption of the NO pathway. To test these hypotheses, we performed studies in anesthetized rats with chronic myocardial infarctions (MIs) produced by coronary artery ligation to determine whether the vasoconstrictor responses to sympathetic nerve stimulation were enhanced in contracting hindlimb and whether these responses could be normalized by experimental interventions that increased NO or decreased O2-.
Materials and Methods
All methods and protocols were approved by the Institutional Animal Care and Research Advisory Committee at the University of Texas Southwestern Medical Center.
Coronary Artery Ligation Model
Female Sprague-Dawley rats were anesthetized
with methohexital sodium (50 mg/kg IP), intubated, and ventilated. A
thoracotomy was performed to expose the heart, and the left
coronary artery was ligated. Sham operations followed the same
procedure without coronary ligation. Studies were performed 6
to 20 weeks after coronary ligation. On completion of each
experiment, the heart was excised and myocardial infarct size was
estimated as described by Chien et
al.21
Experimental Preparation
Rats were anesthetized with ketamine
(80 mg/kg IP) and
-chloralose (60 mg/kg IV) and instrumented as
previously described.3
Briefly, artificially ventilated rats were instrumented with jugular
vein and carotid artery catheters, a Doppler flow probe (Crystal
Biotech) on the left femoral artery, and stimulating electrodes around
the left lumbar sympathetic chain and left sciatic nerve. The left
hindlimb was connected to a force-displacement transducer (FT-10, Grass
Instruments).
Protocol 1: Comparison of Sympathetically
Mediated Vasoconstriction in Resting and Contracting Hindlimb of Sham
and MI Rats
Arterial pressure and femoral blood flow
responses to lumbar sympathetic nerve stimulation (1-ms pulses of 5 V
each at 1, 2.5, or 5 Hz) were measured in resting and contracting
hindlimb. Contractions were produced by sciatic nerve stimulation at 2
to 3 times motor threshold voltage with 100-ms trains of pulses at a
rate of 60 trains/min.
Protocol 2: Effect of Perturbation of the NO
System on Sympathetic Vasoconstriction in Skeletal Muscle of Sham and
MI Rats
Responses to lumbar nerve stimulation were measured
in resting and contracting hindlimb before and after (1) NOS inhibition
with
N-nitro-L-arginine
methyl ester (L-NAME; 5 mg/kg IV) or (2) infusion of the NOS substrate
L-arginine (300 mg/kg
IV).
Protocol 3: Effect of Superoxide Scavenging on
Sympathetic Vasoconstriction in Skeletal Muscle of Sham and MI
Rats
Responses to lumbar nerve stimulation were measured
in resting and contracting hindlimb before and after infusion of the
membrane-permeable
O2- scavenger
tempol (Sigma; 4-hydroxy-2,2,6,6-tetramethyl piperidine-1-oxyl; 180
µmol/kg per hour IA) or tiron (Sigma;
4,5-dihydroxy-1,3-benzene-disulfonic acid; 1 g/kg per hour IA). To
determine whether NOS inhibition prevented the effect of
O2- scavenging,
this protocol was repeated in additional rats pretreated with L-NAME.
The specificity of the scavengers for
O2- was assessed by
measuring the hindlimb vasodilator response to local
intra-arterial injection of acetylcholine (3 µg/kg)
alone, during infusion of an
O2--generating
solution of xanthine (X)/xanthine oxidase (XO) (X, 1 mmol/L; XO, 1
U/mL; 0.02 mL/min IA), and during coinfusion of X+XO and tempol or
tiron.
Western Blot Analysis
Gastrocnemius muscle samples were frozen in liquid
nitrogen and stored at -80°C until analyzed as previously
described.4 NOS was detected
using rabbit polyclonal antibodies raised against the N-terminus of
nNOS (1:4000) or inducible NOS (iNOS; 1:4000) or mouse monoclonal
anti-eNOS (1:1000; Transduction Laboratories). Protein concentrations
were determined using a Bio-Rad DC Protein Assay
kit.
Malondialdehyde (MDA) Assay
Gastrocnemius muscle samples were
homogenized in 10 vol of 20 nmol/L Tris-HCl (pH 7.4) and
centrifuged at 3000g
for 10 minutes at 4°C. The supernatant was assayed for MDA according
to kit instructions (Calbiochem).
Data and Statistical Analysis
Hemodynamic and hindlimb force data
were acquired and analyzed using MacLab hardware and software
(ADInstruments). Statistical analyses of
hemodynamic and force data were performed by
repeated-measures ANOVA with the Dunnett test for within-group
comparisons or the Scheffé test for between-group comparisons.
Biochemical data were compared by unpaired Student
t tests. All data are
presented as
mean±SE.
Results
Twenty sham operations and 104 coronary artery
ligations were performed. Sixty-one rats with the latter treatment
survived, 23 with infarcts <35% of the left ventricle (LV) and 38
with infarcts >35%. Only data from rats with infarcts >35% are
included in this study. Experiments in 2 sham and 4 MI rats were
aborted because of technical difficulties. At the time of study
(14.5±0.8 weeks after surgery), MI rats exhibited significant
ventricular hypertrophy and LV dysfunction
characterized by elevated LV diastolic pressures and
depressed LV systolic pressures and
contractility
(Table 1
). Although all of the MI rats exhibited LV
dysfunction, they were not yet decompensated as evidenced by the lack
of visible ascites and hemodynamics comparable with
those of sham rats
(Table 2
).
|
|
Metabolic Attenuation of
Sympathetic Vasoconstriction Is Impaired in Contracting Hindlimb of MI
Rats
In sham rats, sympathetic nerve stimulation increased
arterial pressure and decreased femoral blood flow and
vascular conductance in resting hindlimb
(Figures 1
and 2
). These sympathetically mediated decreases in
blood flow and conductance were significantly attenuated in contracting
hindlimb of sham rats
(Figures 1
and 2
). In MI rats, sympathetic nerve stimulation
elicited responses in resting hindlimb similar to those observed in
sham rats
(Figures 1
and 2
). The hyperemic response to hindlimb
contraction alone and the force generated by the contracting muscles
also were similar in MI and sham rats
(Table 2
). In contrast, the vasoconstrictor responses to
sympathetic nerve stimulation were significantly greater in the
contracting hindlimb of MI than in that of sham rats, indicating
impaired modulation of sympathetic vasoconstriction
(Figures 1
and 2
).
|
|
NOS Inhibition Reproduces the MI
Phenotype in Sham Rats
The NOS inhibitor L-NAME increased
arterial pressure in both groups of rats, although the mean
increase was greater in the sham (+50±9 mm Hg) than in the MI
(+32±6 mm Hg) rats. In resting hindlimb, the vasoconstrictor
responses to sympathetic nerve stimulation at 2.5 Hz were not altered
by L-NAME in either group of rats
(Figure 3
). In the contracting hindlimbs of sham rats,
sympathetic vasoconstriction was enhanced after L-NAME administration,
producing a phenotype resembling that of the MI rats
(Figure 3
). In contrast, L-NAME had no additional effect on
the already enhanced sympathetic vasoconstriction in the contracting
hindlimbs of the MI rats
(Figure 3
). Similar results were obtained with sympathetic
nerve stimulation at 1 or 5 Hz (data not shown).
|
Exogenous
L-Arginine Reproduces the
Sham Phenotype in MI Rats
Infusion of
L-arginine significantly
reduced arterial pressure in MI rats by 14±5 mm Hg
but had only a minor effect on blood pressure in sham rats. In resting
hindlimb, L-arginine
attenuated the vasoconstrictor responses to sympathetic nerve
stimulation at 2.5 Hz in resting hindlimb to a similar extent in both
groups
(Figure 3
). In the contracting hindlimbs of MI rats,
sympathetic vasoconstriction was further attenuated after
L-arginine infusion,
producing a phenotype resembling that of the sham rats
(Figure 3
). In contrast,
L-arginine had no
additional effect on the greatly attenuated sympathetic
vasoconstriction in the contracting hindlimbs of sham rats
(Figure 3
). Similar results were obtained with sympathetic
nerve stimulation at 1 or 5 Hz (data not shown).
Skeletal Muscle NOS Expression Is Not Altered
in MI Rats
There were no significant differences in eNOS or nNOS
immunoreactivity in gastrocnemius muscle homogenates from
sham and MI rats by Western blot analysis
(Figure 4
). Immunoreactivity to iNOS was not detected
in any of the muscle homogenates (data not
shown).
|
MDA, a Marker of Oxidative Stress, Is Increased
in Skeletal Muscle of MI Rats
MDA, an end product derived from the peroxidation
of polyunsaturated fatty acids and related esters, was increased 3-fold
in gastrocnemius muscle homogenates from MI rats
(0.63±0.15 nmol/mg protein) compared with sham rats (0.21±0.06
nmol/mg protein; P<0.05 vs MI).
Superoxide Scavenging Reproduces the Sham
Phenotype in MI Rats
In normal rats, acetylcholine injected into the
hindlimb increased femoral blood flow by 2.32±0.22 kHz (n=6).
Responses to acetylcholine were reduced by 66±8% in the presence of
the O2--generating
solution of X+XO
(Figure 5A
). Coinfusion of tempol or tiron prevented this
effect of X+XO, indicating effective
O2- scavenging by
these drugs
(Figure 5A
).
|
Tempol and tiron had no significant effects on baseline
hemodynamics in either sham or MI rats, with the
exception of an increased femoral blood flow in MI rats after tempol
infusion (+0.95±0.22 kHz). In resting hindlimb, the vasoconstrictor
responses to sympathetic nerve stimulation at 2.5 Hz were not altered
by tempol in either sham or MI rats or by tiron in MI rats
(Figure 5B
). In the contracting hindlimbs of sham rats,
tempol had no additional effect on the greatly attenuated sympathetic
vasoconstriction
(Figure 5B
). In contrast, in the contracting hindlimbs of MI
rats, sympathetic vasoconstriction was further attenuated after tempol
or tiron infusion, producing a phenotype resembling that of the
sham rats
(Figure 5B
). This effect of tempol in the MI rats was
prevented completely by pretreatment with L-NAME (
conductance in
contracting hindlimb in response to sympathetic stimulation, -27±3%
before tempol and -25±5% after tempol; n=6). Responses were similar
in sham rats pretreated with L-NAME (
conductance in contracting
hindlimb in response to sympathetic stimulation, -34±3% before
tempol and -29±2% after tempol; n=4). Similar results were obtained
with sympathetic nerve stimulation at 1 or 5 Hz (data not
shown).
Sympathetically Mediated Changes in Blood Flow
Alter Hindlimb Contractile Function
In both sham and MI rats, changes in blood flow
elicited by sympathetic nerve stimulation resulted in directionally
similar changes in force output of the contracting hindlimbs
(Figure 6
). In sham rats, blood flow to the contracting
hindlimbs tended to increase during sympathetic nerve stimulation as a
result of increased systemic arterial pressure coupled with
locally attenuated hindlimb vasoconstriction. These increases in
hindlimb blood flow were accompanied by increases in force output of
the contracting muscles. In contrast, in MI rats blood flow to the
contracting hindlimbs decreased during sympathetic stimulation,
resulting in decreases in force output. These sympathetically mediated
decreases in flow and force tended to be reversed after treatment with
L-arginine, tempol, or
tiron in the MI rats.
|
Discussion
Abnormal regulation of the peripheral circulation in heart failure may contribute to hypoperfusion and fatigue of exercising muscles, although the underlying mechanisms are not well defined. Our major new finding is that NO-mediated attenuation of sympathetic vasoconstriction in contracting skeletal muscle is impaired in rats with left ventricular dysfunction due to chronic MI. Our results further suggest that this impairment is mediated at least in part by increased oxidative stress in the contracting muscles. The reduced ability to modulate sympathetic vasoconstriction in contracting muscle of MI rats had significant functional consequences, given that sympathetically mediated decreases in blood flow resulted in decreased force production by the contracting muscles. Together these data suggest that free radicalmediated disruption of the NO system is an important mechanism underlying abnormal sympathetic regulation of skeletal muscle blood flow in heart failure.
We and others previously provided several lines of evidence that skeletal muscle nNOS is an important source of NO that modulates sympathetic vasoconstriction during exercise.4 5 22 Such modulation may constitute an important protective mechanism that serves to optimize blood flow distribution in contracting skeletal muscle. We now have shown that this protective mechanism is defective in a rat model of heart failure. The explanation does not involve decreased NOS expression, because neither eNOS nor nNOS was reduced in skeletal muscle of MI rats. Instead, defective NO-dependent modulation of sympathetic vasoconstriction may have been due to an O2--mediated impairment of the NO pathway in the contracting muscles. This conclusion is predicated on 2 findings. First, in MI rats contraction-induced attenuation of sympathetic vasoconstriction was normalized by tempol or tiron, each of which is a drug that we showed acts as an O2- scavenger in this experimental model. Second, the effect of tempol to normalize responses in MI rats was prevented by pretreatment with L-NAME to inhibit NO production. Taken together, these experiments strongly suggest that the effect of tempol was due to the scavenging of O2- and subsequent relief of NO inhibition rather than to some nonspecific effect of the compound.
Supporting evidence that oxidative stress was increased in skeletal muscle of MI rats was provided by a 3-fold greater MDA concentration in muscle homogenates from MI compared with sham rats. The reaction of oxygen free radicals with polyunsaturated fatty acids in cellular membranes leads to the formation of lipid hydroperoxides that are degraded to a variety of stable products, including MDA. Previous studies have reported increased MDA in plasma of patients with heart failure18 19 20 and in cardiac muscle of MI rats.23 Interestingly, in heart failure patients with elevated plasma MDA at rest, exercise elicited further increases in plasma MDA that were correlated inversely with peak oxygen consumption.20 These data suggested that exercise-induced oxidative stress might contribute to exercise intolerance in heart failure. Our data further advance this concept by providing one potential mechanism by which oxidative stress mediates vascular dysregulation and subsequently impairs contractile function in exercising skeletal muscle of MI rats. Indeed, in our experiments sympathetically mediated decreases in blood flow resulted in decreased force production by the contracting hindlimbs of MI rats.
Oxygen free radicals are produced in the body by numerous
pathways, including mitochondrial oxidases, membrane-bound
oxidoreductases such as NAD(P)H oxidase, extracellular and cytosolic
xanthine oxidases, heme oxygenases, NOS,
cyclooxygenase, and lipoxygenase.
In quiescent skeletal muscle, the production of free radicals
is low and may play a role in cellular signaling. In contracting
muscle, free radical production is accelerated mainly as a
result of the marked increases in cellular metabolism and
oxygen
consumption.24 25 26
The antioxidant defenses in healthy skeletal muscle are usually
adequate to cope with contraction-induced oxidative stress. However, in
heart failure the fine balance between production of free
radicals and endogenous scavenging mechanisms appears to be
disrupted. This imbalance could be mediated by factors such as
catecholamines, angiotensin II, or
cytokines (eg, tumor necrosis factor-
or interleukin-1),
which are known to be elevated in heart failure and have been shown to
activate one or more of the free radicalgenerating
pathways.27 In addition,
oxidative metabolism is impaired in heart failure, possibly
because of decreased expression of oxidative
enzymes28 or functional
block of mitochondrial electron
transport.29 Finally,
antioxidant capacity also may be reduced in heart
failure.19 23
Coexistence of any of these conditions would greatly increase the
propensity for free radical generation, particularly during
metabolically stressful situations such as skeletal muscle
contraction.
Free radical production could occur in a number of
cellular sites in the contracting hindlimb of MI rats, including
skeletal or vascular myocytes, endothelial cells, and
neurons. The vascular endothelium and smooth muscle
have been implicated as sites of free radical production in
pathophysiological states such as hypertension,
atherosclerosis, and heart
failure.27 Recent studies
using the rat coronary artery ligation model of heart failure
have shown that endothelial dysfunction in large and
small arteries studied in vitro can be attributed to increased oxidant
stress and decreased bioavailability of
NO.16 30 In our
study, we speculate that skeletal myocytes were the predominant source
of reactive oxygen species and disruption of the NO pathway for the
following reasons. First, our previous studies suggested that nNOS is a
major source of the NO that attenuates
-adrenergic vasoconstriction
in contracting
muscle.4 5 Although
nNOS expression recently has been demonstrated in arteriolar smooth
muscle,31 skeletal myocytes
constitute by far the largest source of nNOS in muscle. Second,
O2- may not readily
cross cell membranes, and therefore its greatest impact would be in the
cells in which it is
produced.32 Third,
production of both NO and
O2- is enhanced in
contracting skeletal
muscle.24 33
Because NO and O2-
undergo a rapid diffusion-limited reaction, excessive
O2-
production in skeletal muscle of MI rats could reduce the
functional impact of NO by decreasing its bioavailability.
Although direct inactivation of NO by O2- is one possible explanation for the results of our study, other explanations also merit discussion. Plasma levels of the endogenous competitive NOS inhibitor asymmetric dimethylarginine (ADMA) have been reported to be elevated both in heart failure patients and in MI rats,34 35 raising the possibility that NO production is impaired. The mechanisms by which ADMA is elevated in heart failure are unknown, but perhaps oxidative stress is involved given that the enzyme that metabolizes ADMA, ADMA dimethylaminohydrolase, is inhibited by oxidized lipoproteins and cytokines.36 In addition, soluble guanylyl cyclase, which is the downstream effector of NO, may be inhibited directly by O2-.37 Finally, the fact that L-arginine normalized responses in MI rats when given acutely suggests a number of possibilities. L-Arginine may have increased NO production by reversing NOS inhibition caused by elevated ADMA or because of its antioxidant properties may have acted directly to reduce O2-levels in contracting muscle.38 L-Arginine availability may be reduced in heart failure,39 40 possibly as a result of reduced plasma membrane arginine transport or increased activity of cellular arginases, which metabolize L-arginine as part of the urea cycle. The resultant L-arginine deficiency could contribute to oxidative stress not only by decreasing NO production but also by increasing O2- production by NOS.41
Impaired skeletal muscle blood flow responses to exercise in heart failure have been reported in numerous studies,13 14 42 43 44 45 although only a limited number have focused either on the role of the sympathetic nervous system or on the NO system in these abnormal responses. Sympathetic vasoconstriction has been implicated in the attenuated exercise hyperemia in 2 recent studies in heart failure patients,42 43 whereas NO deficiency has been implicated in one study in MI rats13 and one in heart failure patients.14 Our study further advances these concepts by providing a novel unifying hypothesis that links enhanced sympathetic vasoconstriction with NO deficiency as a potential underlying mechanism contributing to hypoperfusion of exercising skeletal muscle in heart failure.
In conclusion, using the rat coronary artery ligation model of heart failure, we have shown that oxidative stressmediated dysfunction of the NO system plays a key role in the impaired modulation of sympathetic vasoconstriction in contracting skeletal muscle. We suggest that this abnormal vascular regulation may contribute to hypoperfusion of skeletal muscle during exercise and thus may be a factor contributing to reduced exercise tolerance in heart failure. Because NO also has been proposed to modulate skeletal muscle metabolism7 and mechanics,6 O2--mediated impairment of the NO system may have additional implications for skeletal muscle function in heart failure.
Acknowledgments
This research was supported by grants from the American Heart Association, Texas Affiliate (Grant 98BR064 to G.D.T.), and the NIH (Grant HL06296 to R.G.V.). We thank Kim Lau for providing the nNOS and iNOS antibodies.
Footnotes
Original received October 27, 2000; revision received February 23, 2001; accepted February 27, 2001.
References
1.
Hansen J,
Thomas GD, Jacobsen TN, Victor RG. Muscle metaboreflex triggers
parallel sympathetic activation in exercising and resting human
skeletal muscle. Am J
Physiol. 1994;266:H2508H2514.
2.
Anderson KM, Faber
JE. Differential sensitivity of arteriolar
3.
Thomas GD,
Victor RG. Nitric oxide mediates contraction-induced attenuation of
sympathetic vasoconstriction in rat skeletal muscle.
J Physiol (Lond). 1998;506:817826.
4.
Thomas GD,
Sander M, Lau KS, Huang PL, Stull JT, Victor RG. Impaired
metabolic modulation of
5.
Sander M, Chavoshan
B, Harris SA, Iannaccone ST, Stull JT, Thomas GD, Victor RG.
Functional muscle ischemia in neuronal nitric oxide
synthase-deficient skeletal muscle of children with Duchenne muscular
dystrophy. Proc Natl Acad Sci
U S A. 2000;97:1381813823.
6.
Kobzik L, Reid MB,
Bredt DS, Stamler JS. Nitric oxide in skeletal muscle.
Nature. 1994;372:546548.
7.
Kobzik L, Stringer
B, Balligand J-L, Reid MB, Stamler JS. Endothelial type
nitric oxide synthase in skeletal muscle fibers: mitochondrial
relationships. Biochem Biophys Res
Commun. 1995;211:375381.
8.
Chang WJ,
Iannaccone ST, Lau KS, Masters BSS, McCabe TJ, McMillan K, Padre RC,
Spencer MJ, Tidball JG, Stull JT. Neuronal nitric oxide synthase and
dystrophin-deficient muscular dystrophy.
Proc Natl Acad Sci
U S A. 1996;93:91429147.
9.
Didion SP, Carmines
PK, Ikenaga H, Mayhan WG. Enhanced constrictor responses of skeletal
muscle arterioles during chronic myocardial infarction.
Am J Physiol. 1997;273:H1502H1508.
10.
Gaballa MA,
Goldman S. Overexpression of endothelium nitric oxide
synthase reverses the diminished vasorelaxation in the hindlimb
vasculature in ischemic heart failure in vivo.
J Mol Cell Cardiol. 1999;31:12431252.
11.
Teerlink JR, Gray
GA, Clozel M, Clozel J-P. Increased vascular responsiveness to
norepinephrine in rats with heart failure is
endothelium dependent. Dissociation of basal and
stimulated nitric oxide release.
Circulation. 1994;89:393401.
12.
Katz SD, Khan T,
Zeballos GA, Mathew L, Potharlanka P, Knecht M, Whelan J. Decreased
activity of the
L-arginine-nitric oxide
metabolic pathway in patients with congestive heart
failure. Circulation. 1999;99:21132117.
13.
Hirai T, Zelis R,
Musch TI. Effects of nitric oxide synthase inhibition on the muscle
blood flow response to exercise in rats with heart failure.
Cardiovasc Res. 1995;30:469476.
14.
Katz SD, Krum H,
Khan T, Knecht M. Exercise-induced vasodilation in forearm circulation
of normal subjects and patients with congestive heart failure: role of
endothelium-derived nitric oxide.
J Am Coll Cardiol. 1996;28:585590.
15.
Comini L,
Bachetti T, Gaia G, Pasini E, Agnoletti L, Pepi P, Ceconi C, Curello S,
Ferrari R. Aorta and skeletal muscle NO synthase expression in
experimental heart failure. J Mol Cell
Cardiol. 1996;28:22412248.
16.
Bauersachs J,
Bouloumié A, Fraccarollo D, Hu K, Busse R, Ertl G.
Endothelial dysfunction in chronic myocardial
infarction despite increased vascular endothelial
nitric oxide synthase and soluble guanylate cyclase
expression. Role of enhanced vascular superoxide production.
Circulation. 1999;100:292298.
17.
Ide T, Tsutsui H,
Kinugawa S, Suematsu N, Hayashidani S, Ichikawa K, Utsumi H, Machida Y,
Egashira K, Takeshita A. Direct evidence for increased hydroxyl
radicals originating from superoxide in the failing
myocardium. Circ
Res. 2000;86:152157.
18.
Díaz-Vélez
CR, García-Castiñeiras S, Mendoza-Ramos E, Hernández-López E.
Increased malondialdehyde in peripheral blood of patients
with congestive heart failure. Am
Heart J. 1996;131:146152.
19.
Keith M,
Geranmayegan A, Sole MJ, Kurian R, Robinson A, Omran AS, Jeejeebhoy KN.
Increased oxidative stress in patients with congestive heart failure.
J Am Coll Cardiol. 1998;31:13521356.
20.
Nishiyama Y,
Ikeda H, Haramaki N, Yoshida N, Imaizumi T. Oxidative stress is related
to exercise intolerance in patients with heart failure.
Am Heart J. 1998;135:115120.
21.
Chien YW, Barbee
RW, MacPhee AA, Frohlich ED, Trippodo NC. Increased ANF secretion after
volume expansion is preserved in rats with heart failure.
Am J Physiol. 1988;254:R185R191.
22.
Lau KS, Grange
RW, Chang W-J, Kamm KE, Sarelius I, Stull JT. Skeletal muscle
contractions stimulate cGMP formation and attenuate vascular smooth
muscle myosin phosphorylation via nitric oxide.
FEBS Lett. 1998;431:7174.
23.
Hill MF, Singal
PK. Right and left myocardial antioxidant responses during heart
failure subsequent to myocardial infarction.
Circulation. 1997;96:24142420.
24.
Reid MB, Haack
KE, Franchek KM, Valberg PA, Kobzik L, West MS. Reactive oxygen in
skeletal muscle, I: intracellular oxidant kinetics and fatigue in
vitro. J Appl Physiol. 1992;73:17971804.
25.
Jenkins RR,
Krause K, Schofield LS. Influence of exercise on clearance of oxidant
stress products and loosely bound iron.
Med Sci Sports Exerc. 1993;25:213217.
26.
Liu J, Yeo HC,
Övervik-Douki E, Hagen T, Doniger SJ, Chu DW, Brooks GA, Ames BN.
Chronically and acutely exercised rats: biomarkers of oxidative stress
and endogenous antioxidants.
J Appl Physiol. 2000;89:2128.
27.
Kojda G, Harrison
D. Interactions between NO and reactive oxygen species:
pathophysiological importance in
atherosclerosis, hypertension, diabetes and heart
failure. Cardiovasc Res. 1999;43:562571.
28.
Simonini A, Long
CS, Dudley GA, Yue P, McElhinny J, Massie BM. Heart failure in rats
causes changes in skeletal muscle morphology and gene expression that
are not explained by reduced activity.
Circ Res. 1996;79:128136.
29.
Ide T, Tsutsui H,
Kinugawa S, Utsumi H, Kang D, Hattori N, Uchida K, Egashira K,
Takeshita A. Mitochondrial electron transport complex I is a potential
source of oxygen free radicals in the failing myocardium.
Circ Res. 1999;85:357363.
30.
Varin R, Mulder
P, Richard V, Tamion F, Devaux C, Henry J-P, Lallemand F, Lerebours G,
Thuillez C. Exercise improves flow-mediated vasodilatation of skeletal
muscle arteries in rats with chronic heart failure. Role of nitric
oxide, prostanoids, and oxidant stress.
Circulation. 1999;99:29512957.
31.
Segal SS, Brett
SE, Sessa WC. Codistribution of NOS and caveolin throughout
peripheral vasculature and skeletal muscle of hamsters.
Am J Physiol. 1999;277:H1167H1177.
32.
Beckman JS,
Freeman BA. Antioxidant enzymes as mechanistic probes of
oxygen-dependent toxicity. In: Taylor AE, Tatalon S, Ward PA, eds.
Physiology of Oxygen Radicals.
Bethesda, Md: American Physiological Society;
1986:3953.
33.
Balon TW, Nadler
JL. Nitric oxide release is present from incubated skeletal muscle
preparations. J Appl
Physiol. 1994;77:25192521.
34.
Usui M, Matsuoka
H, Miyazaki H, Ueda S, Okuda S, Imaizumi T. Increased
endogenous nitric oxide synthase inhibitor in
patients with congestive heart failure.
Life Sci. 1998;62:24252430.
35.
Feng Q, Lu X,
Fortin AJ, Pettersson A, Hedner T, Kline RL, Arnold JMO. Elevation of
an endogenous inhibitor of nitric oxide
synthesis in experimental congestive heart failure.
Cardiovasc Res. 1998;37:667675.
36.
Ito A, Tsao PS,
Adimoolam S, Kimoto M, Ogawa T, Cooke JP. Novel mechanism for
endothelial dysfunction. Dysregulation of
dimethylarginine dimethylaminohydrolase.
Circulation. 1999;99:30923095.
37.
Mülsch A,
Bauersachs J, Schafer A, Stasch JP, Kast R, Busse R. Effect of YC-1, an
NO-independent, superoxide-sensitive stimulator of soluble guanylyl
cyclase, on smooth muscle responsiveness to nitrovasodilators.
Br J Pharmacol. 1997;120:681689.
38.
Wascher TC, Posch
K, Wallner S, Hermetter A, Kostner GM, Graier WF. Vascular effects of
L-arginine: anything beyond
a substrate for the NO-synthase? Biochem
Biophys Res Commun. 1997;234:3538.
39.
Feng Q, Fortin
AJ, Lu X, Malcolm J, Arnold O. Effects of
L-arginine on
endothelial and cardiac function in rats with heart
failure. Eur J Pharmacol. 1999;376:3744.
40.
Hanssen H,
Brunini TMC, Conway M, Banning AP, Roberts NB, Mann GE, Ellory JC,
Mendes Ribeiro AC. Increased
L-arginine transport in
human erythrocytes in chronic heart failure.
Clin Sci. 1997;94:4348.
41.
Pou S, Pou WS,
Bredt DS, Snyder SH, Rosen GM. Generation of superoxide by purified
brain nitric oxide synthase. J Biol
Chem. 1992;267:2417324176.
42.
Lang CC, Rayos
GH, Chomsky DB, Wood AJJ, Wilson JR. Effect of sympathoinhibition on
exercise performance in patients with heart failure.
Circulation. 1997;96:238245.
43.
Shoemaker JK,
Naylor HL, Hogeman CS, Sinoway LI. Blood flow dynamics in heart
failure. Circulation. 1999;99:30023008.
44.
Sullivan MJ,
Knight JD, Higginbotham MB, Cobb FR. Relation between central and
peripheral hemodynamics during exercise in
patients with chronic heart failure. Muscle blood flow is reduced with
maintenance of arterial perfusion pressure.
Circulation. 1989;80:769781.
45.
Wilson JR, Martin
JL, Schwartz D, Ferraro N. Exercise intolerance in patients with
chronic heart failure: role of impaired nutritive flow to skeletal
muscle. Circulation. 1984;69:10791087.
This article has been cited by other articles:
1-
and
2- adrenoceptor constriction to
metabolic inhibition during rat skeletal muscle
contraction. Circ Res. 1991;69:174184.
-adrenergic vasoconstriction in
dystrophin-deficient skeletal muscle. Proc
Natl Acad Sci
U S A. 1998;95:1509015095.
![]()
![]()

![]()
![]()
![]()
S. Koba, Z. Gao, and L. I. Sinoway
Oxidative stress and the muscle reflex in heart failure
J. Physiol.,
November 1, 2009;
587(21):
5227 - 5237.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
H.-J. Wang, Y.-X. Pan, W.-Z. Wang, I. H. Zucker, and W. Wang
NADPH oxidase-derived reactive oxygen species in skeletal muscle modulates the exercise pressor reflex
J Appl Physiol,
August 1, 2009;
107(2):
450 - 459.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
R. B. Nunes, M. Tonetto, N. Machado, M. Chazan, T. G. Heck, A. B. G. Veiga, and P. Dall'Ago
Physical exercise improves plasmatic levels of IL-10, left ventricular end-diastolic pressure, and muscle lipid peroxidation in chronic heart failure rats
J Appl Physiol,
June 1, 2008;
104(6):
1641 - 1647.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. Koba, J. Xing, L. I. Sinoway, and J. Li
Sympathetic nerve responses to muscle contraction and stretch in ischemic heart failure
Am J Physiol Heart Circ Physiol,
January 1, 2008;
294(1):
H311 - H321.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
K. L. Jablonski, D. R. Seals, I. Eskurza, K. D. Monahan, and A. J. Donato
High-dose ascorbic acid infusion abolishes chronic vasoconstriction and restores resting leg blood flow in healthy older men
J Appl Physiol,
November 1, 2007;
103(5):
1715 - 1721.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
J. Xing, S. Koba, V. Kehoe, Z. Gao, K. Rice, N. King, L. Sinoway, and J. Li
Interstitial norepinephrine concentrations in skeletal muscle of ischemic heart failure
Am J Physiol Heart Circ Physiol,
August 1, 2007;
293(2):
H1190 - H1195.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
H. W. H. van Hees, H. F. M. van der Heijden, C. A. C. Ottenheijm, L. M. A. Heunks, C. J. C. Pigmans, F. W. A. Verheugt, R. M. H. J. Brouwer, and P. N. R. Dekhuijzen
Diaphragm single-fiber weakness and loss of myosin in congestive heart failure rats
Am J Physiol Heart Circ Physiol,
July 1, 2007;
293(1):
H819 - H828.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
R. M. Brothers, M. L. Haslund, D. W. Wray, P. B. Raven, and M. Sander
Exercise-induced inhibition of angiotensin II vasoconstriction in human thigh muscle
J. Physiol.,
December 1, 2006;
577(2):
727 - 737.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
S. Koba, Z. Gao, J. Xing, L. I. Sinoway, and J. Li
Sympathetic responses to exercise in myocardial infarction rats: a role of central command
Am J Physiol Heart Circ Physiol,
December 1, 2006;
291(6):
H2735 - H2742.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
W. Zhao, S. A. Swanson, J. Ye, X. Li, J. M. Shelton, W. Zhang, and G. D. Thomas
Reactive Oxygen Species Impair Sympathetic Vasoregulation in Skeletal Muscle in Angiotensin II-Dependent Hypertension
Hypertension,
October 1, 2006;
48(4):
637 - 643.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
F. A Dinenno, S. Masuki, and M. J Joyner
Impaired modulation of sympathetic {alpha}-adrenergic vasoconstriction in contracting forearm muscle of ageing men
J. Physiol.,
August 15, 2005;
567(1):
311 - 321.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
A. Linke, V. Adams, P. C. Schulze, S. Erbs, S. Gielen, E. Fiehn, S. Mobius-Winkler, A. Schubert, G. Schuler, and R. Hambrecht
Antioxidative Effects of Exercise Training in Patients With Chronic Heart Failure: Increase in Radical Scavenger Enzyme Activity in Skeletal Muscle
Circulation,
April 12, 2005;
111(14):
1763 - 1770.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
P. J Fadel, Z. Wang, H. Watanabe, D. Arbique, W. Vongpatanasin, and G. D Thomas
Augmented sympathetic vasoconstriction in exercising forearms of postmenopausal women is reversed by oestrogen therapy
J. Physiol.,
December 15, 2004;
561(3):
893 - 901.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
G. D. Thomas and S. S. Segal
Neural control of muscle blood flow during exercise
J Appl Physiol,
August 1, 2004;
97(2):
731 - 738.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
P. J. Fadel, D. M. Keller, H. Watanabe, P. B. Raven, and G. D. Thomas
Noninvasive assessment of sympathetic vasoconstriction in human and rodent skeletal muscle using near-infrared spectroscopy and Doppler ultrasound
J Appl Physiol,
April 1, 2004;
96(4):
1323 - 1330.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
D. W. Wray, P. J. Fadel, M. L. Smith, P. Raven, and M. Sander
Inhibition of {alpha}-adrenergic vasoconstriction in exercising human thigh muscles
J. Physiol.,
March 1, 2004;
555(2):
545 - 563.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
T. E. Richardson, C. A. Kindig, T. I. Musch, and D. C. Poole
Effects of chronic heart failure on skeletal muscle capillary hemodynamics at rest and during contractions
J Appl Physiol,
September 1, 2003;
95(3):
1055 - 1062.
[Abstract]
[Full Text]
[PDF]
![]()
![]()
![]()

![]()
![]()
![]()
P. J Fadel, W. Zhao, and G. D Thomas
Impaired vasomodulation is associated with reduced neuronal nitric oxide synthase in skeletal muscle of ovariectomized rats
J. Physiol.,
May 15, 2003;
549(1):
243 - 253.
[Abstract]
[Full Text]
[PDF]
![]()
This Article ![]()
![]()
Abstract
![]()
Full Text (PDF)
![]()
All Versions of this Article:
88/8/816
most recent
hh0801.089341v1
![]()
Alert me when this article is cited
![]()
Alert me if a correction is posted
![]()
Services ![]()
![]()
Email this article to a friend
![]()
Similar articles in this journal
![]()
Alert me to new issues of the journal
![]()
Download to citation manager
![]()
Request Permissions ![]()
Citing Articles ![]()
![]()
Citing Articles via HighWire
![]()
Citing Articles via Google Scholar
![]()
Google Scholar ![]()
![]()
Articles by Thomas, G. D. ![]()
Articles by Victor, R. G. ![]()
Search for Related Content
![]()
PubMed ![]()
![]()
Articles by Thomas, G. D.
![]()
Articles by Victor, R. G.
![]()
Related Collections ![]()
![]()
Heart failure - basic studies
![]()
Autonomic, reflex, and neurohumoral control of circulation
![]()
Oxidant stress
|
Circulation Research Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2001 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |